XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive (Loss)/Income
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020   97,549,000      
Beginning balance at Dec. 31, 2020 $ 434,347 $ 10 $ 937,134 $ (261) $ (502,536)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 7,224   7,224    
Issuance of common stock, net of issuance costs (in shares)   121,000      
Issuance of common stock, net of issuance costs 1,689   1,689    
Common stock issued upon exercise of stock options (in shares)   9,000      
Common stock issued upon exercise of stock options 51   51    
Common stock issued upon release of restricted stock units (in shares)   248,000      
Foreign currency translation adjustments (33)     (33)  
Unrealized loss on marketable securities, net (22)     (22)  
Net loss (28,436)       (28,436)
Ending balance (in shares) at Mar. 31, 2021   97,927,000      
Ending balance at Mar. 31, 2021 414,820 $ 10 946,098 (316) (530,972)
Beginning balance (in shares) at Dec. 31, 2020   97,549,000      
Beginning balance at Dec. 31, 2020 434,347 $ 10 937,134 (261) (502,536)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Foreign currency translation adjustments (123)        
Unrealized loss on marketable securities, net (139)        
Net loss (111,131)        
Ending balance (in shares) at Sep. 30, 2021   98,143,000      
Ending balance at Sep. 30, 2021 346,000 $ 10 960,180 (523) (613,667)
Beginning balance (in shares) at Mar. 31, 2021   97,927,000      
Beginning balance at Mar. 31, 2021 414,820 $ 10 946,098 (316) (530,972)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 8,234   8,234    
Issuance of common stock, additional issuance costs (4)   (4)    
Common stock issued upon release of restricted stock units (in shares)   17,000      
Common stock issued under employee stock purchase plan (in shares)   176,000      
Common stock issued under employee stock purchase plan 526   526    
Foreign currency translation adjustments (39)     (39)  
Unrealized loss on marketable securities, net (62)     (62)  
Net loss (44,333)       (44,333)
Ending balance (in shares) at Jun. 30, 2021   98,120,000      
Ending balance at Jun. 30, 2021 379,142 $ 10 954,854 (417) (575,305)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 5,326   5,326    
Common stock issued upon release of restricted stock units (in shares)   23,000      
Foreign currency translation adjustments (51)     (51)  
Unrealized loss on marketable securities, net (55)     (55)  
Net loss (38,362)       (38,362)
Ending balance (in shares) at Sep. 30, 2021   98,143,000      
Ending balance at Sep. 30, 2021 346,000 $ 10 960,180 (523) (613,667)
Beginning balance (in shares) at Dec. 31, 2021   98,381,000      
Beginning balance at Dec. 31, 2021 316,185 $ 10 964,965 (714) (648,076)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 5,381   5,381    
Common stock issued upon exercise of stock options (in shares)   15,000      
Common stock issued upon exercise of stock options 3   3    
Common stock issued upon release of restricted stock units (in shares)   371,000      
Foreign currency translation adjustments 14     14  
Unrealized loss on marketable securities, net (723)     (723)  
Net loss (37,908)       (37,908)
Ending balance (in shares) at Mar. 31, 2022   98,767,000      
Ending balance at Mar. 31, 2022 282,952 $ 10 970,349 (1,423) (685,984)
Beginning balance (in shares) at Dec. 31, 2021   98,381,000      
Beginning balance at Dec. 31, 2021 $ 316,185 $ 10 964,965 (714) (648,076)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock issued upon exercise of stock options (in shares) 15,000        
Foreign currency translation adjustments $ (50)        
Unrealized loss on marketable securities, net (1,189)        
Net loss (121,800)        
Ending balance (in shares) at Sep. 30, 2022   99,728,000      
Ending balance at Sep. 30, 2022 208,337 $ 10 980,156 (1,953) (769,876)
Beginning balance (in shares) at Mar. 31, 2022   98,767,000      
Beginning balance at Mar. 31, 2022 282,952 $ 10 970,349 (1,423) (685,984)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 4,942   4,942    
Common stock issued upon release of restricted stock units (in shares)   5,000      
Common stock issued under employee stock purchase plan (in shares)   499,000      
Common stock issued under employee stock purchase plan 362   362    
Foreign currency translation adjustments (34)     (34)  
Unrealized loss on marketable securities, net (339)     (339)  
Net loss (43,761)       (43,761)
Ending balance (in shares) at Jun. 30, 2022   99,271,000      
Ending balance at Jun. 30, 2022 244,122 $ 10 975,653 (1,796) (729,745)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 4,503   4,503    
Common stock issued upon release of restricted stock units (in shares)   457,000      
Foreign currency translation adjustments (30)     (30)  
Unrealized loss on marketable securities, net (127)     (127)  
Net loss (40,131)       (40,131)
Ending balance (in shares) at Sep. 30, 2022   99,728,000      
Ending balance at Sep. 30, 2022 $ 208,337 $ 10 $ 980,156 $ (1,953) $ (769,876)